Emerging Growth Research News Releases

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Thu, 04 Dec 2025 15:19:00 -0500

New York, New York--(Newsfile Corp. - December 4, 2025) - Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (NASDAQ: OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00, representing approximately 1,487% upside from the Company's December 3rd closing price of $0.63.The flash report highlights a major non-binding licensing term sheet announced by OSRH with BCM Europe AG (BCME) valued at $815 million for the global development and...

Emerging Growth Research Initiates Coverage on First Phosphate Corp. with a Buy Rating and C$4.93 Price Target

Thu, 04 Dec 2025 09:00:00 -0500

New York, New York--(Newsfile Corp. - December 4, 2025) - Emerging Growth Research today announced the initiation of coverage on First Phosphate Corp. (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0), establishing a Buy rating with a 12-month price target of C$4.93, representing approximately 467% upside from the Company's recent closing price of C$0.87 on December 3rd, 2025.The initiation report positions First Phosphate as a uniquely advantaged Western phosphate platform specifically designed for the...

Emerging Growth Research Reiterates Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Q3:25 Results

Mon, 01 Dec 2025 14:35:00 -0500

New York, New York--(Newsfile Corp. - December 1, 2025) - Emerging Growth Research today announced the release of its Q3:25 quarterly update on SBC Medical Group Holdings, Inc. (NASDAQ: SBC), reiterating a Buy-Extended rating and maintaining its 12-month price target of $9.00, representing significant upside from the Company's recent closing price of $3.57 on November 28, 2025.The quarterly update highlights SBC's sequential stabilization in revenue and operating profit during Q3:25, strong cash...

Emerging Growth Research Releases Q3 2025 Update Report on 22nd Century Group

Wed, 26 Nov 2025 10:21:00 -0500

New York, New York--(Newsfile Corp. - November 26, 2025) - Emerging Growth Research today released its latest quarterly update report on 22nd Century Group, Inc. (NASDAQ: XXII), highlighting the Company's now cash-rich balance sheet, full debt repayment, settlement of a $9.5 million insurance case, and stabilization of its Contract Manufacturing Operations (CMO). The updated report also reflects management's revised outlook for EBITDA breakeven, now expected in Q3 2026.Key Highlights from the...

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

Mon, 20 Oct 2025 11:40:00 -0400

New York, New York--(Newsfile Corp. - October 20, 2025) - Emerging Growth Research today announced the initiation of coverage on OSR Holdings, Inc. (NASDAQ: OSRH) with a Buy-Emerging rating and a 12-month price target of $10.00, representing over 1,600% upside from the Company's recent closing price of $0.58.The initiation report highlights OSR Holdings' innovative biotech portfolio, expanding 4th-party logistics (4PL) business, and pending acquisition of Woori IO, a noninvasive glucose...

Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target

Fri, 17 Oct 2025 11:07:00 -0400

New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on Immuron Limited (Nasdaq: IMRN) with a Buy-Extended rating and a 12-month price target of $4.00, representing over 80% upside from the Company's recent closing price of $2.20.The initiation report highlights Immuron's proprietary polyclonal antibody platform, strong revenue growth from its over-the-counter product Travelan®, and an expanding clinical pipeline addressing...

Emerging Growth Research Initiates Coverage on SBC Medical Group Holdings, Inc. with Buy-Extended Rating and $9.00 Price Target

Thu, 04 Sep 2025 09:00:00 -0400

New York, New York--(Newsfile Corp. - September 4, 2025) - Emerging Growth Research today announced the initiation of coverage on SBC Medical Group Holdings, Inc. (NASDAQ: SBC) with a Buy-Extended rating and a 12-month price target of $9.00, more than double the Company's recent closing price of $4.06.The initiation report highlights SBC's dominant position in Japan's cosmetic treatment industry, its strong cash position, and growing global expansion strategy, while also acknowledging near-term...

Emerging Growth Research Releases Q2 2025 Update Report on 22nd Century Group

Fri, 22 Aug 2025 15:17:00 -0400

New York, New York--(Newsfile Corp. - August 22, 2025) - Emerging Growth Research today released its latest quarterly update report on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q2 2025 results. The report reflects ongoing operational restructuring under new management and revised outlook for EBITDA breakeven pushed to Q2 2026 due to slower-than-expected CMO stabilization and VLN® rollout timing.22nd Century Group Q2 2025 Financial Highlights:Q2 2025 revenue of $4.1...

Emerging Growth Research Releases Q1 2025 Update Report on 22nd Century Group

Wed, 21 May 2025 09:00:00 -0400

New York, New York--(Newsfile Corp. - May 21, 2025) - Emerging Growth Research today released its latest quarterly update report on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q1 2025 results. The report reflects the continued operational progress made under new management and the outlook for meaningful financial improvement in 2025.22nd Century Group Q1 2025 Financial Highlights:Q1 2025 revenue of $6.0 million, up 48% from Q4 2024Q1 2025 gross profit improved to $(0.6)...

Emerging Growth Research Releases Quarterly Update Report on 22nd Century Group (XXII)

Thu, 10 Apr 2025 09:00:00 -0400

Sheridan, Wyoming--(Newsfile Corp. - April 10, 2025) - Emerging Growth Research is pleased to release its latest quarterly update on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q4 2024 results. The report reflects the continued operational progress made under new management and the outlook for meaningful financial improvement in 2025.To read the full report, please visit: http://www.EmergingGrowth.com/profile/xxii/Q4 2024 Financial Highlights:Revenue was $4.0 million, down...